GlassScriptPhysician profile
Jeffrey Schenck
NPI 1447713409
$4,431.55
in general payments reported to CMS, 2019-2025
18 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $40.00 · 2023: $1,172 · 2024: $1,651 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,004 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,004.01 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.18 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $876.32 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $519.03 | 2023-2025 | |
| Eko Health, INC. | $389.00 | 2021-2022 | |
| Lilly USA, LLC | $332.49 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Axsome Therapeutics, INC. | $301.54 | 2023-2025 | Symbravo, Auvelity |
| Novo Nordisk INC | $199.95 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $121.89 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $100.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $85.45 | 2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.80 | 2023-2024 | Relistor, Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $61.57 | 2024 | Spravato |
| Insulet Corporation | $39.50 | 2025 | Omnipod |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $29.17 | 2023 | Zypitamag |
| Dexcom, INC. | $26.11 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $22.68 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schenck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.